Felbinac Trometamol Injection — Competitive Intelligence Brief

Felbinac Trometamol Injection (Felbinac Trometamol Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-steroidal anti-inflammatory drug (NSAID). Area: Pain Management / Rheumatology.

phase 3 Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Pain Management / Rheumatology Small molecule

Target snapshot

Felbinac Trometamol Injection (Felbinac Trometamol Injection) — Shijiazhuang Yiling Pharmaceutical Co. Ltd. Felbinac trometamol is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Felbinac Trometamol Injection TARGET	Felbinac Trometamol Injection	Shijiazhuang Yiling Pharmaceutical Co. Ltd	phase 3	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Tinoridine HCl	Tinoridine HCl	Takeda	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
NSAID (Ketorolac/Ibuprofen)	NSAID (Ketorolac/Ibuprofen)	Thomas Jefferson University	marketed	Non-steroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
NSAID's	NSAID's	Saglik Bilimleri Universitesi Gulhane Tip Fakultesi	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Oral tablets of Alphintern®	Oral tablets of Alphintern®	Ain Shams University	marketed	Non-steroidal anti-inflammatory drug (NSAID)	COX-2
NSAID therapy	NSAID therapy	Rabin Medical Center	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Metamizole Sodium	Metamizole Sodium	Insel Gruppe AG, University Hospital Bern	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-steroidal anti-inflammatory drug (NSAID) class)

1. Ain Shams University · 1 drug in this class
2. IBSA Institut Biochimique SA · 1 drug in this class
3. Insel Gruppe AG, University Hospital Bern · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Rabin Medical Center · 1 drug in this class
6. Saglik Bilimleri Universitesi Gulhane Tip Fakultesi · 1 drug in this class
7. Shijiazhuang Yiling Pharmaceutical Co. Ltd · 1 drug in this class
8. Takeda · 1 drug in this class
9. Thomas Jefferson University · 1 drug in this class